ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2025
Trends in hospital antibacterial consumption: a retrospective analysis of reimbursement data, Belgium 2017 to 2022.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antibiotic Consumption Patterns in Three Romanian Hospitals: A Five-Year Retrospective Study.Antibiotics (Basel, Switzerland) · 2026Article
- Antimicrobial Consumption and Resistance Dynamics Across Healthcare Level: Global Evidence and Stewardship Implications.Pathogens (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUNDThe COVID-19 pandemic has challenged efforts to optimise rational antibacterial use due to uncertainties in treatment protocols.AIMWe investigated the impact of COVID-19 on hospital antibacterial consumption in Belgium from 2017 to 2022, relative to the general and hospitalised population.METHODSWe analysed national reimbursement data using defined daily doses (DDD) and three metrics: DDD/1,000 inhabitants/day (DID), DDD/1,000 patient days (PD) and DDD/1,000 admissions. We performed linear regressions to analyse 6-year trends (2017-2022) and estimated predicted consumption from 2020 to 2022 using the compound annual growth rate from 2017 to 2019. To assess the impact of COVID-19, we compared observed and predicted relative changes in antibacterial consumption between 2019 (pre-pandemic) and 2020 (early pandemic) and between 2019 and 2022 (late pandemic).RESULTSFrom 2019 to 2020, hospital antibacterial consumption (anatomical therapeutic chemical (ATC) J01) decreased by 12% in DID but increased by 5% and 7% in DDD/1,000 PD and DDD/1,000 admissions, respectively. From 2017 to 2022, systemic antibacterials consumption declined significantly only when expressed in DID. Although all systemic antibacterial subclasses were used less than predicted between 2020 and 2022 when expressed in DID, hospital-based metrics showed higher consumption, except for macrolides and amphenicols. Broad-spectrum antibacterial consumption decreased from 2017 to 2022 when expressed in DID but fluctuated with hospital metrics, peaking in 2020, and exceeded forecasts.CONCLUSIONCOVID-19 altered trends in hospital antibacterial consumption, with contrasting patterns depending on the metric used, underline the importance of hospital-specific surveillance to support targeted stewardship and preparedness efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.